Just three weeks ago the company forged a collaboration with Dainippon Sumitomo and at the end of 2007 AstraZeneca signed a $400 million deal. Turning off genes that cause disease has become a hot field in biotechnology. Silence Therapeutics has developed AtuRNAi, a short interfering RNA (siRNA) molecule which is chemically modified to improve stability, reduce manufacturing costs and increase yield. - check out the press release Realted Articles: Silence gets green light for siRNA trial Silence shouts about $400M AstraZeneca deal